Physician profile
Muhammad Anwar
NPI 1891720975
$8,938.20
in general payments reported to CMS, 2019-2025
25 companies · $2,400 in 2025
The $2,400 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $773 · 2021: $1,125 · 2022: $340 · 2023: $1,060 · 2024: $2,847 · 2025: $2,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,425 · Food and Beverage: $2,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,425.10 |
| Food and Beverage | $2,881.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,102.64 | 2022-2025 | Dragonfly Opstar, Optis, Mitraclip |
| Philips North America LLC | $1,199.71 | 2024 | (Bq9) Coronary Ivus |
| Medtronic, INC. | $1,154.42 | 2024-2025 | Micra, Aurora Ev-Icd Mri Surescan, Symplicity G3 |
| Amgen INC. | $814.71 | 2019-2025 | Repatha, Repatha |
| Baylis Medical Company INC | $625.71 | 2021 | |
| Janssen Pharmaceuticals, INC | $458.31 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $426.45 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $292.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Edwards Lifesciences Corporation | $263.73 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $253.90 | 2020-2024 | |
| Ge Healthcare | $222.64 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $218.79 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.73 | 2019-2025 | Jardiance |
| Pfizer INC. | $136.85 | 2019-2024 | |
| Boston Scientific Corporation | $125.00 | 2023-2025 | Watchman Flx, Cds Broad Portfolio Offering |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $108.50 | 2024-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $94.33 | 2020-2025 | Camzyos, Eliquis |
| Glaxosmithkline, LLC. | $76.44 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $56.84 | 2019-2023 | |
| Inspire Medical Systems, INC. | $24.67 | 2025 | Inspire |
| Abbvie INC. | $20.42 | 2021 | |
| Ethicon US, LLC | $19.98 | 2024 | Dermabond |
| Scpharmaceuticals INC. | $19.11 | 2025 | |
| Astellas Pharma US INC | $18.28 | 2021 | |
| Medtronic Vascular, INC. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Anwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.